Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag ADR (OP:BAYRY)

9.880 -0.270 (-2.66%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jun 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,574,640
Open 9.710
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.15
Today's Range 9.584 - 9.890
52wk Range 7.030 - 14.85
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Bayer to Present First Full FIND-CKD Results Investigating KERENDIA® (finerenone) in Non-Diabetic Chronic Kidney Disease at ERA 2026
From Bayer
Via Business Wire
News headline image
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
From Bayer
Via Business Wire

Performance

YTD
-10.9%
-10.9%
1 Month
-8.8%
-8.8%
3 Month
-16.3%
-16.3%
6 Month
+12.7%
+12.7%
1 Year
+36.5%
+36.5%

More News

Read More
News headline image
Recursion Pharmaceuticals Just Hit a 52-Week Low. Is This Former Nvidia Holding a Smart Buy Now? ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
ASCO 2026: Bayer to Present New Data Across Oncology Portfolio
From Bayer
Via Business Wire
News headline image
Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
From Bayer
Via Business Wire
News headline image
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
From Bayer
Via Business Wire
News headline image
AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement
From Bayer
Via Business Wire
News headline image
Bayer Partners with Luke Bryan to Donate 1 Million Meals Through Feeding America® to Expand Access to Food and Nutrition in Rural Communities
From Bayer
Via Business Wire
News headline image
Investigational PET Tracer Iodine 124 Evuzamitide from Bayer Met Primary Endpoints in Phase III Study in Patients Suspected to Have Cardiac Amyloidosis
From Bayer
Via Business Wire
News headline image
Bayer to Acquire Perfuse Therapeutics to Complement Ophthalmology Pipeline
From Bayer
Via Business Wire
News headline image
Bayer to Present 13 Abstracts From Its Stroke Franchise at ESOC 2026, Including Two Late-breaking Analyses From the Phase III OCEANIC-STROKE Trial of Asundexian
From Bayer
Via Business Wire
News headline image
New Study Highlights Societal Optimism Toward Breakthrough Science, and Rising Anxiety About How Fast the World Is Changing
From Bayer
Via Business Wire
News headline image
Record-Breaking US Soybean Planting Pace Clouds Futures Market
Via MarketMinute
Topics Economy Energy World Trade
News headline image
Midwest Planting Delays Loom as NOAA Predicts Heavy April Rains
Via MarketMinute
News headline image
USDA Stuns Markets as April WASDE Raises Farm Gate Prices Amid Domestic Supply Crunch
Via MarketMinute
Topics Economy Energy
News headline image
Bayer Announces Leadership Change Within Pharmaceuticals’ Worldwide Markets Organization in the U.S. to Support Company’s Full Growth Potential
From Bayer
Via Business Wire
News headline image
Multiplatinum Rapper, Actor Ludacris Partners with One A Day® to Help People Realize that Health Does Not Need to Be Ludacris
From Bayer
Via Business Wire
News headline image
The Great Unbundling: How AI’s Insatiable Hunger is Driving a Corporate Divestiture Gold Rush
Via MarketMinute
Topics Artificial Intelligence Economy
News headline image
KERENDIA® (finerenone) Meets Primary Endpoint in Investigational Phase III FIND-CKD Study in Patients with Non-Diabetic Chronic Kidney Disease
From Bayer
Via Business Wire
News headline image
New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments
From Bayer
Via Business Wire
News headline image
The Section 122 Pivot: How a 10% Global Tariff is Reshaping the 2026 Market Landscape
Via MarketMinute
Topics Economy Electric Vehicles Government
News headline image
The Strategic Crossroads of FMC Corporation: A 2026 Research Deep Dive
Via Finterra
Topics Economy Intellectual Property World Trade
News headline image
The Great Grain Pivot: USDA Forecasts Record Soy Surge as Corn Retreats in 2026
Via MarketMinute
Topics Energy

Frequently Asked Questions

Is Bayer Ag ADR publicly traded?
Yes, Bayer Ag ADR is publicly traded.
What exchange does Bayer Ag ADR trade on?
Bayer Ag ADR trades on the OTC Traded
What is the ticker symbol for Bayer Ag ADR?
The ticker symbol for Bayer Ag ADR is BAYRY on the OTC Traded
What is the current price of Bayer Ag ADR?
The current price of Bayer Ag ADR is 9.880
When was Bayer Ag ADR last traded?
The last trade of Bayer Ag ADR was at 06/02/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.